Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-167-4 | CAS number: 79-01-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- two-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-guideline (NTP protocol) study (GLP status not known), some restrictions, adequate for assessment
- Principles of method if other than guideline:
- NTP protocol Reproductive Assessment by Continuous Breeding. This system involves four successive tasks. Task 1 is a preliminary 14 day toxicity study, conducted so that appropriate dose levels for the subsequent tasks can be selected. Task 2, the continuous breeding phase, involves a 14 week cohabiting phase during which reproductive performance is monitored. In Task 3, an optional "cross-over" mating trial is conducted; control males are mated with high dose females and high dose males are mated with control females. This is to determine whether any adverse effect seen in Task 2 is mediated through males of females. In Task 4 the reproductive performance of the F1 offspring taken from the Task 2 final litters is assessed. The test substance is administered continuously through Tasks 2, 3 and 4 (except during the Task 3 mating phase).
As an additional task, the open field behaviour of the F1 generation was evaluated at 21 and 45 days of age. - GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- CDF (COBS(F344)/CrlBr) inbred albino rats were obtained from the Charles River Breeding Laboraties, Inc., Kingston, NY, and were quarantined and examined upon arrival.
- Route of administration:
- oral: feed
- Vehicle:
- other: microencapsulated in a gelatin/sorbitol shell
- Details on exposure:
- Data from a two week dose-range-finding study (Task 1) were used to set exposure concentrations for the Task 2 continuous cohabitation study.
Trichloroethylene was microencapsulated in a gelatin/sorbitol shell and administered by incorporation in the diet. - Details on mating procedure:
- Task 2: the continuous breeding phase consisted of a 7 days premating exposure, following by a 98 days cohabitation period and a 28 days segregation period.
Task 4: at 81 +/- 10 days of age, a male and a female F1 animal from different litters within the same treatment group were cohabited for 7 days. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of the feed formulations used for the dose-range finding study indicated that these ranged from 96% to 111% of the desired TCE concentrations.
Analysis of the task 2 feed formulatons at 6 weeks intervals indicated that during the course of task 2, there was some variability in the actual concentration of TCE in the feed. For task 2, week 1 samples, the 0.15%, 0.30% and 0.60% formulations assayed at 33%, 66% and 87% of the theoretical concentratrion of TCE. Similarly, during week 6 of task 2, the 0.15%, 0.30% and 0.60% TCE formulation assayed at 27%, 71% and 82% of the theoretical concenctration, respectively. Samples of formulation from each of the dose levels administered during week 12 ad 18 of task 2 assayed at 101-114% of the theorectical concentration. - Duration of treatment / exposure:
- administration is continuously through Tasks 2, 3 and 4 (except during the Task 3 mating phase)
- Frequency of treatment:
- continuously via feed
- Details on study schedule:
- The protocol consisted of 4 tasks.
Task 1 was a 14-day range-finding study to aid in the selection of dose levels for Task 2 (continuous breeding). 8 males and 8 females (8 weeks of age) per dose group were given TCE (nominal concentrations 0.0, 0.60, 1.20, 2.40, 3.61 and 4.82%) in their feed for 14 days.
Based on the acute toxicity results from Task 1, dietary levels of 0.0, 0.15, 0.30 and 0.60% TCE were selected for the continuous breeding phase (Task 2). The continuous breeding phase consisted of a 7-d premating exposure, following by a 98-d cohabitation period and a 28-d segregation period.
Task 3 utilized the control and high dose parental rats (0.60%) from task 2 in a crossover breeding design in order to determine the affected sex. The following 4 pairs were distinguished (male/female): Control/Control; Control/0.60% TCE; 0.60% TCE/Control; 0.60% TCE/0.60% TCE. Cohabitation for 7 days followed by separation to allow the female to deliver her litter.
Task 4 evaluated fertility and reproductive performance in the F1 offspring from the final Task 2 litters of the control group and all three dose groups.
As an additional task, the open field behaviour of the F1 generation was evaluated at 21 and 45 days of age. - Remarks:
- Doses / Concentrations:
0.15%, 0.30% and 0.60%
Basis:
nominal in diet - Remarks:
- Doses / Concentrations:
75, 150 and 300 mg/kg bw/day
Basis:
nominal in diet - No. of animals per sex per dose:
- Task 1: 8/sex/dose
Task 2: 20 pairs/dose
Task 4: 20 male and 20 female F1 generation offspring from the control and high dose groups - Control animals:
- yes
- Details on study design:
- Selected F1 offspring were evaluated for open field behavior at 21 and 45 days of age, prior to the conduct of task 4.
- Parental animals: Observations and examinations:
- In the F0 and F1 males the following parameters were evaluated:
-liver weight
-kidneys/adrenals weight
-left testis/epididymis weight
-right testis weight
-right epididymis weight
-number of cauda epididymal sperm per mg cauda tissue
-sperm motility and morphology.
The prostate, seminal vesicles/coagulating glands, a portion of the median lobe of the liver, kidneys/adrenals, and the remaining carcass (with top of cranium removed) were preserved in neutral-buffered 10% formalin. The left testis/epididymis and testis were fixed for 24 h in Bouin's solution and then transferred to 70% ethanol, the right epididymis (cauda) was used for sperm analysis.
In the F0 and F1 females the following parameters were evaluated:
-liver weight
-kidneys/adrenals weight.
The ovaries and oviducts were removed and preserved for 24 hours in Bouin's solution and then transferred to 70% ethanol. The uterus and the upper half of vagina were excised and preserved in 10% formalin. A portion of the median lobe of the liver, the kidneys with attached adrenals and the carcass (with top of cranium removed) also were preserved in 10% formalin. Histopathological evaluation of the preserved excised tissues was performed for the control group and the highest dose group evaluated for the F0 males and females, and the control/low/mid and high dose groups for the F1 males/females. - Oestrous cyclicity (parental animals):
- In the F0 and F1 females the following parameters were evaluated:
the ovaries and oviducts were removed and preserved for 24 hours in Bouin's solution and then transferred to 70% ethanol. The uterus and the upper half of vagina were excised and preserved in 10% formalin. - Sperm parameters (parental animals):
- In the F0 and F1 males the following parameters were evaluated:
-left testis/epididymis weight
-right testis weight
-right epididymis weight
-number of cauda epididymal sperm per mg cauda tissue
-sperm motility and morphology.
The prostate and seminal vesicles/coagulating glands were preserved in neutral-buffered 10% formalin. The left testis/epididymis and testis were fixed for 24 h in Bouin's solution and then transferred to 70% ethanol, the right epididymis (cauda) was used for sperm analysis. - Litter observations:
- litter size, proportion of live pups, litter weight and sex ratio of the pups
- Postmortem examinations (parental animals):
- See above
- Postmortem examinations (offspring):
- See above
- Statistics:
- not specified in the available report
- Reproductive indices:
- Reproductive performance was monitored by counting the number of F1 generation litters produced by each breeding pair and recording on the day of birth the litter size, proportion of live pups, litter weight and sex ratio of the pups.
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, treatment-related
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- parental toxicity
- Effect level:
- 75 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: reduced body weight gain, increased relative liver weight, depressed postpartum dam weights
- Remarks on result:
- other: Generation: P and F1 (migrated information)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- effects on fertility
- Effect level:
- 75 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: reductions in the number of litters born to continuously bred animals at 300 mg/kg/day and in the litter size at 150 and 300 mg/kg/day, dose levels at which other toxic effects were elicited
- Remarks on result:
- other: Generation: P and F1 (migrated information)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 75 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- other: reduced liter size at 150 and 300 mg/kg
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 75 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Litter size decreases at 150 and 300 mg/kg
- Reproductive effects observed:
- not specified
Reference
During the crossover mating trial (Task 3), the proportion of detected matings was significantly depressed in the mating pairs with treated partners compared to the control pairs. However, the fertility and reproductive performance of breeding pairs containing one TCE-treated partner was not different form control breeding pairs. Specifically, TCE exposure of either the male or the female partner had no significant effect on the number of pairs able to produce a live litter, the number of live pups per litter, the proportion of pups born alive, the sex of pups born alive, absolute live pup weight, or adjusted live pup weight.
The postpartum weight of 0.60% TCE-treated dams was significantly reduced compared to control dams.
F0 male and female rats used in the mating trials were weighed and necropsied at the completion of Task 3. There was some evidence of generalised toxicity in the F0 generation, observed as a slight reduction in bodyweight gain for both males and females at all treatment levels, although for males a clear dose-response relationship was not apparent. Mean absolute body weight of the males exposed to 0.60% TCE was significantly depressed compared to control males. Absolute liver and kidney/adrenal weight were significantly elevated for the TCE-treated males compared to controls. This pattern held true when male organ weights were adjusted for body weight at necropsy. In addition, combined left testes/epididymis mean weight was increased (by about 3%) in the high dose group. However, sperm assessment indicated no significant effect of TCE treatment on sperm motility, concentration or morphology. Furthermore, no treatment related histopathological effects were observed in the male reproductive organs. For female rats, mean absolute body weight in the 0.60% TCE-treated group was significantly depressed compared to the control group. Mean absolute liver and kidney/adrenal weight were unaffected by treatment. When female organ weights were adjusted for body weight at necropsy, both liver and kidney/adrenal weight in the treated group were significantly elevated compared to the combined control group.
No significant treatment-related gross or histological lesions were noted in any tissues examined microscopically from male or female rate exposed to 0.60% TCE in the feed, compared to vehicle-treated control rats. Evaluation of the vaginal mocusa indicated there were no consistent treatment-related changes in vaginal cyclicity. Histopathological changes observed but not associated with treatment included bile duct proliferation in the hepatic portal regions of both male and female rats, minimal to slight focal hepatocellular necrosis in male rats, and focal accumulations of macrophages in the hepatic parenchyma of female rats. Tubular regeneration and tubular casts were observed in the kidneys of rats of both sexes.
On day 21, 10 F1 litters from the 0% TCE group and the surviving F1 litters in the 0.15, 0.30 and 0.60% TCE group were selected for weaning and rearing to sexual maturity. At 21 days of age, 6 animals were randomly selected from each litter for behavioral assessment by open field activity. Equal representation of males and females within each litter was obtained whenever possible. On the afternoon of day 21, the pups were brought to the behavioral testing room with their dams in their home cages, and habitated to the testing environment for at least 30 minutes. The pups were then tested individually in the open field. The open field test consisted of a three-minute trial period during which the following measures were recorded: 1) latency to traverse the first grid; 2) total number of traverses, 3) rearing, 4) grooming, and 5) defecation and urination. Continuous exposure to TCE upto 0.60% in the feed via the mother (in utero) and throughout lactation to day 21 resulted in a significant dose-related trend toward an increase in the time required for males and females (sexes combined) to traverse the first grid, but had no significant effect on any other measure open field evaluation. No effect of treatment was noted for locomotor activity or miscellaneous behavior when the animals were retested at 45 days of age. Therefore, TCE appeared to have only a slight effect on the ability of 21 day old F1 offspring to react to a novel environment, which was not evident at 45 days of age.
After the behavioral evaluation, all F1 offspring were separated from their mothers. F1 offspring were housed by sex in groups of two or three rats and maintained on the same feed level of TCE as their Task 2 parents. At 81 +/- 10 days of age, a male and female from different litters within the same treatment group were cohabited for 7 days. The pairs were then separated and the females allowed to deliver their litters. Continuous exposure to the F1 rats to TCE in the feed via their mothers and from birth to 81 +/- 10 days of age had no significant effect on indices of mating or fertility or any measure of reproductive performance including live litter size, proportion of pups born alive, sex of pups born alive, or absolute or adjusted live pup weight. The postpartum weights of the F1 dams were significantly decreased compared to controls in all TCE treatment groups.
A reduction in bodyweight gain, which followed a clear dose-related pattern, was seen in the retained F1 generation animals of both sexes at all treatment levels. The F1 rats were necropsied 4 weeks after the 7-day cohabitation period. Mean male body weight and absolute right testis weight were significantly depressed in the treated groups compared to controls. Combined mean kidney/-adrenal weight for 0.15% TCE-treated males was significantly decreased, left testis/epididymis weight was significantly depressed in the 0.60% group, and prostate weight was significantly depressed in the 0.30% group. There were no significant differences between control and TCE-treated males for mean absolute liver, right epididymis, or seminal vesicle weight. When F1 male organ weights were adjusted for body weight at necropsy, increased bodyweight-related liver weight in males at all treatment levels (by 16% at the highest dose) and in females in the middle and high dose groups (by about 10% at the highest dose) and seminal weight was elevated in the 0.30% TCE group compared to controls. There were no other significant differences among the control and treatment groups for any other mean adjusted organ weight.
Sperm assessment for the F1 males indicated that continuous exposure to TCE in the feed via their mothers and throughout lactation and weaning to day 81 +/- 10 resulted in a significant increase in the percent abnormal sperm in the 0.30% TCE group, but no other adverse effects on sperm motility, concentration, or sperm morphology. F1 female body weights at necropsy were significantly depressed below controls in all TCE treatments groups. Mean absolute liver weight was unaffected by TCE treatment, and combined kidney/adrenal weights were significantly depressed below control only in the 0.15% TCE group. When F1 female organ weight were adjusted for body weight at necropsy, adjusted mean liver weight was significantly elevated over controls in the 0.30% and 0.60% TCE groups, but adjusted kidney/adrenal weight was not significantly affected by TCE treatment.
Histopathological examination of tissues from F1 male and female rats revealed no treatment-related lesions in any of the tissues of either sex. Microscopic changes in the kidney that were noted but not considered to be treatment-related were similar to those observed in the F0 rats, and included evidence of chronic progressive nephropathy. In addition, prostatitis was observed in a few male rats in each treatment group.
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 75 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- good
Additional information
It is not possible to draw any firm conclusions about the reproductive toxicity of trichloroethylene on the basis of the available human data.
Animal Data:
Two oral (diet) continuous breeding studies are available, one in rats and one in mice. In the rat study, trichloroethylene produced general toxicity (reduced body weight gain, increased relative liver and kidney weights) at all doses (75, 150 and 300 mg/kg bw/day), while reducing reproductive indices only at the middle and high dose levels. Thus, trichloroethylene was not found to be a selective reproductive toxicant in rats.
In mice, trichloroethylene exposure produced significant hepatic and renal toxicity (increased weights and microscopic lesions), reduced sperm motility in both generations, and slight reductions in neonatal bodyweight and survival in the high dose group (750 mg/kg bw/day). No effects on reproductive performance were observed. No effects were observed at 187 and 350 mg/kg bw/day. The data suggest that the hepatic/renal/perinatal mortality were more severe than the relatively moderate reductions in sperm motility. Based on the available studies with rats and mice, effects on fertility are not considered critical in case of trichloroethylene.
Short description of key information:
Two good quality continuous breeding studies conducted by the NTP (one in rat and one in mouse) showed that trichloroethylene is not a selective reproductive toxicant with a lowest NOAEL of 75 mg/kg bw.
Justification for selection of Effect on fertility via oral route:
Reliable reproductive toxicity study.
Effects on developmental toxicity
Description of key information
A guideline-compliant developmental study with rats showed no developmental effects at any exposure level tested. Maternal effects were observed at the highest tested concentration (600 ppm), so the NOAEL is 150 ppm.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study, no restrictions, fully adequate for assessment
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Qualifier:
- according to guideline
- Guideline:
- other: Directive 87/302/EEC: Teratogenicity Test – Rodent and Non-Rodent Species
- Qualifier:
- according to guideline
- Guideline:
- other: s Japan MAFF Toxicity Testing Guidelines for Teratogenicity Studies
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- Trichloroethylene was obtained from the Dow Chemical Company (Freeport, TX). A purity of 99.0 +/- 0.05% was established via an area gas chromatographic procedure. Infrared spectroscopy, mass spectroscopy, and nuclear magnetic resonance spectroscopy confirmed the structure and chemical identity.
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Housing: mated females were housed singly in stainless-steel wire mesh cages
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 40-60
- Air changes (per hr): 12-15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Animals were exposed in 2-cubic-meter stainless steel and glass Rochester-style exposure chambers under dynamic airflow conditions. Chamber airflow was maintained at approximately 450 liters per minute (L/min), which was sufficient to provide 12-15 air changes per hour and thus maintain normal concentrations of oxygen. The various concentrations of TCE were generated using a glass J-tube method (Miller et al., 1980). Compressed air and TCE vapors were diluted and mixed with room air.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentrations TCE were measured twice per hour with a Miran 1A infrared spectrometer (Foxboro/Wilks, South Norwalk, CT) at a wavelength of 11.85 micrometer. A PC-based data acquisition and control system was used (CAMILE TG, Camile products, LLD, Indianapolis, IN) to calculate and store the TCE chamber concentrations.
- Details on mating procedure:
- Virgin female rats were mated overnight at the supplier with male rats (one female to one male). The day on which evidence of positive copulation was established was documented as GD 0.
- Duration of treatment / exposure:
- day 6-20 of gestation
- Frequency of treatment:
- 6 hours/day, 7 days/week
- Duration of test:
- 21 days
- Dose / conc.:
- 50 ppm (nominal)
- Dose / conc.:
- 150 ppm (nominal)
- Dose / conc.:
- 600 ppm (nominal)
- No. of animals per sex per dose:
- 27
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale:
maternal toxicity at highest dose,
- Rationale for animal assignment (if not random): Random assignment to groups
- - Maternal examinations:
- Maternal necropsies were performed on GD 21. Dams were evaluated for clinical signs, body weight and feed consumption. Liver and kidney weights were measured.
- Ovaries and uterine content:
- On the scheduled day of euthanasia each surviving female underwent a gross necropsy where gravid uterine weights were recorded, along with the number of corpora lutea, uterine implantations, resorptions, and live/dead fetuses.
- Blood sampling:
- Not examined
- Fetal examinations:
- All fetuses were weighed, sexed, and examined for external alterations. Fetuses were examined under blind conditions. Approximately one half of the fetuses were examined for visceral alterations, which were done using the fresh in situ examination ("Staple's") technique (Staples, 1974; Stuckhardt and Poppe, 1984). The study also employed free-hand sectioning of the fetal head as part of the visceral examination. Skeletal examinations were conducted on the remaining fetuses in each litter following staining with Alizarin Red Sand Alcian Blue for identification of bone and cartilage, respectively (McLeod, 1980; Kimmel and Trammel, 1981; Webb and Byrd, 1994).
- Statistics:
- The litter was used as the statistical unit for analysis for litter/fetal data. Continuous data were tested in both studies for homogeneity of variance using Bartlett's test at alpha = 0.01 (Bartlett, 1937). In this study, the raw data were tested. Based on the results of Bartlett'stest, data were analyzed using either parametric or nonparametric tests. Analysis of variance was used, followed by a Dunnett's test (Winer, 1971), or followed by a Bonferroni corrected Wilcoxon Rank Sum test (Miller, 1966). For the TCE study, frequency of pre-implantation loss, resorptions per litter, resorptions per fetal population, and fetal variations and malformations were analyzed using a censored Wilcoxon test with Bonferroni's correction. In addition, pregnancy rates were analyzed using the Fisher's exact probability test (Siegel, 1956) with Bonferroni's correction. Fetal sex ratios were analyzed using a binomial distribution test (Steel and Torrie, 1960).
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- 22% decrease in body weight gain in the first 3 days of exposure at 600 ppm
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Observed differences between groups were minor, not beyond historical control, and/or not dose responsive.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- All rats survived to scheduled maternal necropsy, no clinical observations were noted that could be attributed to treatment.
No statistically significant differences in mean body weight or feed consumption were noted between the treated groups and the control. At 600 ppm, mean body weight gain was reduced by 22% during the first 3 days of dosing (GD 6-9) and found to be statistically significant. No other significant body weight changes were noted at 600 ppm, or the remaining dose levels (50 and 150 ppm) of TCE. No statistically identified differences in feed consumption were found for any TCE treatment group, as compared to the control. Anatomic pathology revealed slightly increased relative kidney weight (~6% increase at 0.521 and 0.525 g/100, respectively) at 50 and 600 ppm TCE, which was statistically identified; however, these changes were not considered treatment related as they were within the historical control range (0.458-0.530 g/100) and lacked a dose-response relationship. A slight (~6%) increase in relative liver weight at 600 ppm. TCE was statistically identified, with the value just barely outside the historical control range (3.455-3.872g/100). As liver weights at the low dose were higher than at the middle dose, the degree of change at the high dose was small, and in consideration of previous toxicity data, this change was most likely spurious.
At necropsy no gross maternal observations were noted in any of the TCE treatment groups. No significant differences were observed for pregnancy rates, number of corpora lutea, implantations, viable fetuses per litter, percent pre- and post-implantation loss, resorption rates, fetal sex ratios, or gravid uterine weights in rats exposed to any dose level of TCE. An increase in mean male fetal body weight at 150 ppm was noted and statistically identified, but this was not considered test article related, as no such effect was observed at the high-dose level (600 ppm) of TCE. - Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
All rats survived to scheduled maternal necropsy, no clinical observations were noted that could be attributed to treatment.
No statistically significant differences in mean body weight or feed consumption were noted between the treated groups and the control. At 600 ppm, mean body weight gain was reduced by 22% during the first 3 days of dosing (GD 6-9) and found to be statistically significant. No other significant body weight changes were noted at 600 ppm, or the remaining dose levels (50 and 150 ppm) of TCE. No statistically identified differences in feed consumption were found for any TCE treatment group, as compared to the control. Anatomic pathology revealed slightly increased relative kidney weight (~6% increase at 0.521 and 0.525 g/100, respectively) at 50 and 600 ppm TCE, which was statistically identified; however, these changes were not considered treatment related as they were within the historical control range (0.458-0.530 g/100) and lacked a dose-response relationship. A slight (~6%) increase in relative liver weight at 600 ppm. TCE was statistically identified, with the value just barely outside the historical control range (3.455-3.872g/100). As liver weights at the low dose were higher than at the middle dose, the degree of change at the high dose was small, and in consideration of previous toxicity data, this change was most likely spurious.
At necropsy no gross maternal observations were noted in any of the TCE treatment groups. No significant differences were observed for pregnancy rates, number of corpora lutea, implantations, viable fetuses per litter, percent pre- and post-implantation loss, resorption rates, fetal sex ratios, or gravid uterine weights in rats exposed to any dose level of TCE. An increase in mean male fetal body weight at 150 ppm was noted and statistically identified, but this was not considered test article related, as no such effect was observed at the high-dose level (600 ppm) of TCE. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 ppm (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- not examined
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
There were no statistically identified differences in the incidence of fetal malformations or variations in any of the TCE treatment groups, as compared to the control. One control fetus showed multiple cardiac malformations, consisting of a right-sided arotic arch, along with missing carotid and subclavian arteries. No fetal malformations were identified at 50 ppm. At 150 ppm, there was one fetus with dilated cerebral ventricles, without atrophy of brain tissue. At 600 ppm, one fetus was identified with cutis laxa (a condition of redundant, loosely adherent skin; also called cutis laxis) and another fetus was identified with unilateral anophthalmia. As these alterations occurred in single fetuses, without a clearly defined dose-response relationship, they were not considered toxicologically meaningful. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 600 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- changes in postnatal survival
- external malformations
- skeletal malformations
- visceral malformations
- Abnormalities:
- not specified
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 600 ppm (nominal)
- Treatment related:
- no
- Conclusions:
- Maternal Toxicity was reflected in a 22% lower body weight gain see in the first 3 days of exposure to 600 ppm.
There were no signs of developmental toxicity among any treatment group. - Executive summary: